. 2022 Sep 10;43(12):6919–6928. doi: 10.1007/s10072-022-06374-4

Table 1.

FARPRESTO aims

Aims of the FARPRESTO study
Primary aim	To identify risk factors of phenoconversion in alpha-synucleinopathies by means of collection of different biomarkers (clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers)
Secondary aims	Describe clinical and sociodemographic characteristics of iRBD To longitudinally assess the development of alpha-synucleinopathy To estimate phenoconversion rate at 3, 5, 7, and 10 years To evaluate quality of life and subjective sleep quality by means of validated questionnaires To assess the correlation between phenoconversion, cognitive performance, and loss of normal muscle atony during REM sleep To identify RBD phenotype through different biomarkers (clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers) To validate vPSG criteria to RBD diagnosis

Aims of the FARPRESTO study

Primary aim

To identify risk factors of phenoconversion in alpha-synucleinopathies by means of collection of different biomarkers (clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers)

Secondary aims

Describe clinical and sociodemographic characteristics of iRBD

To longitudinally assess the development of alpha-synucleinopathy

To estimate phenoconversion rate at 3, 5, 7, and 10 years

To evaluate quality of life and subjective sleep quality by means of validated questionnaires

To assess the correlation between phenoconversion, cognitive performance, and loss of normal muscle atony during REM sleep

To identify RBD phenotype through different biomarkers (clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers)

To validate vPSG criteria to RBD diagnosis